<DOC>
	<DOCNO>NCT01593059</DOCNO>
	<brief_summary>This registry clinical post-market evaluation Orsiro LESS subject require coronary revascularization Drug Eluting Stents ( DES ) .</brief_summary>
	<brief_title>BIOFLOW-III Romania Satellite Registry</brief_title>
	<detailed_description>For majority Coronary Artery Disease ( CAD ) , treatment Percutaneous Transluminal Coronary Angioplasty ( PTCA ) provide high initial procedural success . However , medium long-term complication range rather immediate elastic recoil vessel contraction longer process like smooth muscle cell proliferation excessive production extra cellular matrix , thrombus formation atherosclerotic change like restenosis angiographic re-narrowing . The reported incidence restenosis PTCA range 30 % -50 % . Such rate recurrence serious economic consequence . Bare Metal Stents ( BMS ) , design address limitation PTCA , reduce angiographic clinical restenosis rate de novo lesion compare PTCA alone decrease need CABG . BMS substantially reduce incidence abrupt artery closure , restenosis still occur 20 % -40 % case , necessitate repeat procedure . The invention Drug Eluting Stents ( DES ) significantly improve principle BMS add antiproliferative drug ( directly immobilise stent surface release polymer matrix ) , inhibit neointimal hyperplasia . The introduction DES greatly reduce incidence restenosis result good safety profile compare BMS systemic drug administration . These advantage low cost compare surgical intervention make DES attractive option treat coronary artery disease . This observational registry design investigate collect clinical evidence clinical performance safety Orsiro Drug Eluting Stent System all-comers patient population daily clinical practice .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<criteria>Symptomatic coronary artery disease Subject sign informed consent data release Subject geographically stable willing participate followup assessment Subject â‰¥ 18 year Elective PCI DES Subject sign inform consent data release Pregnancy Known intolerance aspirin , clopidogrel , ticlopidine , heparin anticoagulation / antiplatelet therapy require PCI , stainless steel , Sirolimus contrast medium Planned surgery within 6 month PCI unless dual antiplatelet therapy maintain Currently participate another study primary endpoint reach yet .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>International</keyword>
	<keyword>Multicenter</keyword>
	<keyword>Observational registry</keyword>
	<keyword>Orsiro Drug Eluting Stent ( DES )</keyword>
	<keyword>Stenting</keyword>
	<keyword>Treatment Coronary Artery Disease</keyword>
	<keyword>Coronary revascularization</keyword>
	<keyword>Percutaneous Coronary Intervention</keyword>
	<keyword>STEMI</keyword>
	<keyword>NSTEMI</keyword>
	<keyword>Ischemia</keyword>
	<keyword>Angina</keyword>
	<keyword>Subgroups</keyword>
	<keyword>Acute Myocardial Infarction</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Small Vessels</keyword>
	<keyword>Chronic Total Occlusion ( CTO )</keyword>
</DOC>